NTRK fusion in NSCLC is rare (~0.1-0.5%). Larotrectinib and entrectinib are FDA tumor-agn...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NTRK-FUSION-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-NTRK-FUSION |
|---|---|
| Variant | NTRK1/3 fusion (rare ~0.1-0.5%) |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | entrectinib monotherapy (preferred for CNS disease), larotrectinib monotherapy |
| Evidence summary | NTRK fusion in NSCLC is rare (~0.1-0.5%). Larotrectinib and entrectinib are FDA tumor-agnostic; NSCLC subset of pooled trials shows durable responses including CNS activity (entrectinib has superior CNS penetrance). Tumor-agnostic actionability — NTRK testing is part of comprehensive NGS panels in NSCLC. |
Notes
ESCAT IA (tumor-agnostic actionability). OncoKB Level 1. Detection: RNA-NGS preferred; pan-TRK IHC as screen.
Used By
No reverse references found in the YAML corpus.